

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A pharmaceutical ocular composition, comprising, consisting or consisting essentially of levodopa, an antioxidant and an aqueous carrier.
2. A composition for inhibiting the progression or development of a visual disorder, comprising, consisting or consisting essentially of levodopa, an antioxidant and an aqueous carrier.
3. The composition according to claim 1 or claim 2, wherein the antioxidant is selected from ascorbic acid, phenolic acids, sorbic acid, sodium bisulfite, sodium metabisulfite, acetyl cysteine, sodium thiosulfate, ethylene diamine tetraacetic acid, sodium nitrite, ascorbyl stearate, ascorbyl palmitate, alpha-thioglycerol, erythorbic acid, cysteine hydrochloride, citric acid, tocopherol or vitamin E, tocopherol acetate, dibutylhydroxytoluene, soybean lecithin, sodium thioglycolate, butylhydroxyanisole, propyl gallate, uric acid, melatonin, thiourea, and salts and combinations thereof.
4. The composition according to claim 3, wherein the antioxidant is ascorbic acid.
5. The composition according to any one of claims 1-4, further comprising an inhibitor of aromatic L-amino acid decarboxylase.
6. The composition according to claim 5, wherein the inhibitor of aromatic L-amino acid decarboxylase is selected from carbidopa, benserazide, methyldopa and combinations thereof.
7. The composition according to claim 6, wherein the inhibitor of aromatic L-amino acid decarboxylase is carbidopa.
8. The composition according to any one of claims 5-7, wherein the ratio of levodopa to the inhibitor of aromatic L-amino acid decarboxylase is in the range of from 20:1 to 1:1.
9. The composition according to claim 8, wherein the ratio of levodopa to the inhibitor of aromatic L-amino acid decarboxylase is 4:1.
10. The composition according to any one of claims 1-9, wherein the composition further comprises a dopamine receptor agonist.
11. The composition according to claim 10, wherein the dopamine receptor agonist is selected from quinpirole, apomorphine, ropinirole, pramipexole, dextramipexole, piribedil, rotigotine, bromocriptine, lisuride, cabergoline, 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, pergolide, calidopa, dihydrexidine, doxathrine, propylnorapomorphine, quinagolide, roxindole, sumanirole, fenoldopam, ergocornine, 1-phenyl-2,3,4,5-tetrahydro-(1*H*)-3-benzazepine-7,8-diol, 2-(*N*-phenethyl-*N*-propyl)amino-5-hydroxytetralin, dihydroergotamine,

(1*R*,3*S*)-1-(aminomethyl)-3-phenyl-3,4-dihydro-1*H*-isochromene-5,6-diol, carmoxirole, fenoldopam, and salts and combinations thereof.

12. The composition according to any one of claims 1-11, wherein the composition further comprises a GABA receptor antagonist.

5 13. The composition according to claim 12, wherein the GABA receptor antagonist is selected from bicuculline, flumazenil, gabazine, phenylenetetrazol, (1,2,5,6-tetrahydropyridin-4-yl)methylphosphinic acid, (3-aminopropyl)(cyclohexylmethyl)phosphinic acid, and salts and combinations thereof.

10 14. The composition according to any one of claims 1-13, wherein the composition further comprises a muscarinic acetylcholine receptor antagonist.

15 15. The composition according to claim 14, wherein the muscarinic acetylcholine receptor antagonist is selected from atropine, pirenzepine, himbacine, hyoscine, cyclopentolate, ipratropium, oxitropium, tropicamide, oxybutynin, 15 tolterodine, diphenhydramine, dicycloverine, flavoxate, tiotropium, trihexyphenidyl, solifenacin, darifenacin, benztropine, mebeverine, procyclidine, acridinium, and salts and combinations thereof.

20 16. The composition according to any one of claims 1-15, wherein the aqueous carrier is selected from saline, water, aqueous buffer, an aqueous solution comprising water and a miscible solvent, and combinations thereof.

17. The composition according to any one of claims 1-16, wherein levodopa is in solubilized form.

18. The composition according to any one of claims 1-17, wherein the pH of the composition is in the range of from 5 to 8.

25 19. The composition according to claim 18, wherein the pH of the composition is in the range of from 5.2 to 7.4.

20. The composition according to claim 19, wherein the pH of the composition is in the range of from 5.5 to 6.

30 21. The composition according to any one of claims 1-20, wherein the composition is formulated for topical administration to the eye.

22. The composition according to claim 21, wherein the composition is in the form of an eye drop.

35 23. The composition according to claim 21 or claim 22, wherein the composition is formulated for penetration of levodopa through the corneal epithelium.

24. The composition according to any one of claims 1-20, wherein the composition is formulated for direct injection into the eye.

25. The composition according to claim 24, wherein the composition is formulated for intravitreal administration.

26. A method of inhibiting the progression or development of a visual disorder in a subject, comprising administering to the subject the composition
5 according to any one of claims 1-25.

27. Use of a composition according to any one of claims 1-25 for inhibiting the progression or development of a visual disorder in a subject.

28. A composition according to any one of claims 1-25 for use in inhibiting the progression or development of a visual disorder in a subject.

10 29. The method, use or composition according to any one of claims 26-28, wherein the visual disorder is selected from a visual disorder associated with diabetic retinopathy, a visual disorder associated with Parkinson's disease, and myopia.

15 30. The method, use or composition according to claim 29, wherein the visual disorder is myopia.

31. A process for preparing the composition according to claim 1 or claim 2, comprising dissolving levodopa in the aqueous carrier at a pH in the range of from 0.5 to 2.5, adding the antioxidant to the composition and adjusting the pH of the composition to a pH in the range of from 5 to 8.

20 32. The process according to claim 31, wherein the levodopa is dissolved in the aqueous carrier at a pH of 2.

33. The process according to claim 31 or claim 32, wherein the pH of the composition is adjusted to a pH in the range of from 5.5 to 6.

25 34. A pharmaceutical ocular composition formulated for topical administration to the eye, comprising, consisting or consisting essentially of levodopa, an antioxidant and an aqueous carrier.

35. A topical composition for inhibiting the progression or development of a visual disorder, comprising, consisting or consisting essentially of levodopa, an antioxidant and an aqueous carrier.

30